Novo Nordisk CEO looks beyond weight loss to longevity and aesthetics
- Posted on June 7, 2026
- By Fortune
- 1 Views
- 1 min read
Novo Nordisk CEO looks beyond weight loss to longevity and aesthetics
Novo itself is beginning to generate data suggesting semaglutide may actually affect biological processes linked to aging, not just body weight.